investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I Need Help,
I agree with your comments regarding both the overall market and your outlook on CTIX.
I believe what ever the overall market brings: doing your DD, and selecting individual stocks, that continue to shown progress in providing products that address unmet medical need gives one the best chance to outperform the overall market.
CTIX in one of the stocks I am betting on for both the long and short term.
Great profit!
I hope we can added at least another 40%, because I think I bought your shares.
Bio,
Keep sharing your opinion.
Your last few posts have a lot of great information, and wouldn't it be a shame to have all of the good gains from the general market and the great gains from the biotech market washed away.
I know there are some, including myself, that feel that if not for the FED propping up the markets, they would be at much lower levels right now. Some how I don't feel very secure that there is a solid base under the world economy or world financial markets.
I see a lot of potential in CTIX and have been building a position, last buy was yesterday at $1.76.
If this technology proves successful, I don't know where the PPS will stop.
A doubling of the PPS since November. Someone likes the progress NVIV is making in preparation for the initiation of the clinical trial.
Definitely worth the risk, for the huge potential reward.
Tom,
Let's start with how INO stock performed in 2013: 480% gain
Like I've stated before I start investing in INO in Nov 2012 and have not been out of the stock since that time, neither have I ever been short INO.
I have bought and sold many shares during that time, and despite not being a "TA Expert" have had the fortune to realize a 6 figure profit from INO stock. Just to test your idea that you need to be a "TA Expert" to play INO, I checked my profit if I would have held all my share until now.
Guess what? my profit would have been almost exactly the same.
Some traders rely on TA and miss out on runs of certain stocks. They buy too late and sell too early.
Some wait for buy signals that never come and get frustrated that they miss out on profits.
Some get frustrated enough to constantly talk down the stock, to either try to buy lower or short the stock.
Others do the DD, have experienced how the stock has performed, see Big Pharma take an interest in INO. They decide that they would rather be ON the rollercoaster than watching it from the ground.
GLTA
I hope we can have a civil discussion, on the board, regarding interesting information and the direction INO stock will take in the short and long term.
I have only been an investor here since Nov. 2012 and since then have never been completely out of the stock. This means I have ridden the ups and downs, ie.: $.80 to $.46 to $3.00 to $1.20 to $3.00 to $1.68 to $3.00 to here.
I have traded the stock, not completely on a technical basis, but as we have had rises and resistance, I have taken profits, only to buy in again on the dips. I am diversified, as much as one can be trading only biotechs, and I try not be be over weighted in any one stock. No matter how bullish I am on the short or long term future of the stock.
Do we have "bashers" that post on the board, using anything, including TA to talk the PPS down? I believe so.
Do we have posters giving their legitimate opinion on the TA of INO?
Yes, but many times adding downside targets in the hopes of following the TA to lower PPS entry points.
Do we have long term shareholders that might have over-weighted positions in INO, and in-turn are very sensitive to any perceived negative post on the future direction of INO PPS? Yes
We all have an opinion or an interest in INO stock or we wouldn't post on the board, but hopefully everyone will try to support their opinion, by sharing their DD.
No one on the board, in the 15 months I have traded INO, has talked me out of my shares, or effected the price of INO stock where I haven't been able to react and keep my profits high.
By the way, I have never shorted INO. Good luck to myself and all the INO longs.
DVAX
Great vaccine
Great Cash Position
Moving up on great volume.
weak,
Whether you want to see it from this perspective or not, the comment about ONCS being further along than INO refers to the:
THREE phase II clinical trial ONCS currently has running vs. the:
ONE phase II clinical trial INO currently has on going.
Phase II clinical trials usually means, that if successful, the treatments are closer to commercialization than pre-clinical or Phase I trial treatments.
I currently have similar amounts invested in both INO and ONCS, and I am expecting excellent returns on both of these investments.
Did not write the article, but the quote sits near my computer as a constant reminder for me to be patient with the stock picks I have made.
Being patient with ONCS has rewarded longs with opportunities to buy on the dips.
Continuing to add to my position and will be holding tight in 2014.
"The stock market is simply the transfer of wealth from the impatient to the patient." Warren Buffet
Add shares @ $.476.
MiamiGent,
We've missed you on the board during INO's latest run from the $1.60"s to $3.00.
I guess if your investment style is to ride negative AF musing on the short side, you might have missed what was going on in 2013, with INO stock.
I will provide a link, information that all the INO longs on the board are well aware of, but something you might have missed.
http://www.forbes.com/sites/matthewherper/2014/01/02/the-best-and-worst-performing-biotech-stocks-of-2013/
I'm glad you feel satisfied that your opinions on INO are shared by someone that also missed INO's long side in 2013.
The longs on this board will just have to be SATISFIED with the 480% upside we enjoyed last year.
Whether we lost many of our contributors to the INO Ihub board or not, 2013 was a tremendous year for INO and the stock.
Whether you bought and held or bought on the dips and sold the resistance you were able to make a very nice profit. INO accounted for about 75% my profit for 2013. I want to thank all those that contributed to the board in 2013, and hope to see more comments in the coming year.
http://www.forbes.com/sites/matthewherper/2014/01/02/the-best-and-worst-performing-biotech-stocks-of-2013/
I feel that with all the positives surrounding INO in 2013 and the performance of the stock, we have plenty of investors and upcoming catalysts to drive the stock much higher in the coming months and years.
I look for a very profitable 2014.
Value Investor-Looking for undervalued biotechs.
Try to catch biotechs that I am watching after: stock offerings annoucements, negative news, negative articles, and evaluate whether they might be oversold or near a bottom of there descent.
DD, get in low pps, don't chase a stock, sell at resistance levels
Achillion Pharmaceuticals Inc-1/2 position 68% off 52wk high
AEterna Zentaris Inc-3/4 position 59% off 52wk high
Cellceutix Corp-3/4 position 16% off 52wk high
DARA BioSciences Inc- 3/4 position 47% off 52wk high
Dynavax Technologies Corp- sold position $1.18 to $1.98
Inovio Pharmaceuticals Inc-1/2 position Buy under $2 pps resistance $3.00 take profits
InVivo Therapeutics Holdings Corp-1/2 position 61% off 52wk high
Mast Therapeutics Inc-1/2 position 45% off 52wk high
Navidea Biopharmaceuticals Inc- Full position 43% off 52wk high
NeoStem Inc- 1/4 position 30% off 52 week high
NovaBay Pharmaceuticals Inc-Full position 40% off 52wk high
Northwest Biotherapeutics Inc-1/4 position bounce play
OncoSec Medical Inc-1/2 position near 52wk high took some profit
RXi Pharmaceuticals Corp- 3/4 position 73% off 52wk high
Titan Pharmaceuticals Inc- 1/5 position 75% off 52wk high
ARCA Biopharma Inc-1/5 position 72% off 52wk high
Chelsea Therapeutics International Ltd- 1/3 position near 52 wk high. Look to take profit
Inovio-INO
52 week price change: 449.5% 3rd best biotech during that span.
Current PPS: $2.83
Has encountered strong resistance, for the 3rd time this year, in the $3.00 pps range.
Top line data release for phase 2 HPV trial set for Mid 2014.
Company seeking partners, to follow Roche partnership of Sept 2013, for other clinical candidates.
4th best: CHTP: 443.8%
5th best: ACAD: 432.6%
Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
Partnerships: Roche, University of Pennsylvania, Merck and Company, University of Southhampton, HIV Trials Network, National Institute of Allergy and Infectious Disease, U.S. Military HIV Research Program, PATH Malaria Vaccine Initiative (established with a grant from the Bill & Melinda Gates Foundation), and National Cancer Institute.
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800. In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.
VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.
And a chart a trader should love:
Forgive my ignorance, I've only been following this board for a little over a year.
INO, if it been anything, it hasn't been boring. Whether your DD favors or cautions against an investment, money to be made this last six months.
Comments or a reason for lack of comments.
It would be funny if it wasn't all the low ball predictions that are coming true on a daily basis.
We keep hearing the predictions of a rebound and target prices in the cents, but sadly none of them are getting closer to being true.
I have a small long position and would love to see a rebound, but it doesn't seem we're heading in that direction.
I guess I will believe we're headed positive only when I see it in the PPS.
I believe that ONCS has near term catalysts that will take the stock higher in the short term.
I see no reason, if the near term trial data is positive, that ONCS will continue to:
1. Be a great investment both short and long term
2. Be attractive as a partner moving forward
3. Be the target of a buyout offer from large pharma
October offering at approx. $1.08 pps. Funds used to do FDA required Phase 3 trial.
We had some predicting that nothing this year would move DVAX pps and that they would not buy until price reach $1.00.
DVAX pps 10/25/2013= $1.25
DVAX pps 12/23/2013= $1.99
60% Gain Rewarding the LONGS
Looks like, if today's action is any indicator, that $2.03 was a nice entry point.
INO and ONCS both use electroporation for delivery of their vaccines and anti-cancer drugs.
At this point, I don't believe they have any treatments or vaccines they are studying for the same indication.
But because they use similar delivery methods, you could see positive or negative news effect the pps of the other stock, to some degree.
Both companies have shown outstanding pre-clinical and early phase clinical data. INO has garnered most of the funding and clinical headlines, but ONCS has current phase 2 trials for metastatic melanoma, and Merkel cell carcinoma. Currently Merkel cell carcinoma has no fda approved treatment.
A year ago I first invested in INO and had an average PPS of $.63. I have since turned over those shares into profit and I currently have a smaller position with an average $2.01 PPS.
I hope and have feeling I maybe in the same position, with ONCS, I was a year ago with INO. I have a average PPS of $.26 and hope to see significant upward movement in the PPS in the next year.
What I have found to be risky, about biotech investing, is to hold a large position during the time pivotal clinical trial data will be released, into an ADCOM meeting, or a PDUFA data. Those are the times you can see huge downward price action in a stock on negative news. That can happen no matter how much DD you do because you never know what the company or the FDA knows or what their agendas are. You can comment that those are the instances when you see upward price action as well. While that maybe true, you can also see perceived good news, Roche partnership, that should move the stock up, but come to find out that the partnership might already be reflected in the current price of the stock.
Their are plenty of other examples of "buy the rumor and sell the news" that we seen this year in biotech investing.
I do like some diversification, even in biotech investing, as long as my DD can justify the investment.
It is definitely not: INO vs. ONCS.
These two companies are linked by technology, among other things.
This link, and I'm sure you can find others, will give you some background.
http://www.xconomy.com/san-diego/2012/02/08/oncosec-medical-advancing-inovios-technology-against-cancer/
I feel that both companies have very bright futures, and that is why I am long both ONCS and INO.
I, as many others on the board, thought we might see a 30%-40% drop.
Bio stocks and stockholders tend to over react to news, and coupled with the recent 50+% drop, I feared the worst.
The recovery from yesterdays AH low was unexpected and at the end of the day the 5% drop, I can live with.
For those on the board that feel NAVB is not worth more than $2 pps, at $2.05 it might be a good time to sell and move on to another investment.
I still feel that there is enough potential near term upside in NAVB to keep me long, at least for the 1st part of 2014.
As a relative "newbie" what do I know, since I've only been following the stock for a year.
Buy, Sell, or Hold, good luck to all.
SVFC is selling shares to raise capital at the rate of 500 shares for each $1.00 raised.
That's 50,000,000 shares to raise $100,000.
How far does $100,000 go toward the expenses of even a small company like SVFC?
So you've watched the SVFC pps mid-July at $.07, and said to yourself: " If only I can get my shares for $.002s, I will load up because there would be little to no risk at that level, but there would be too much risk in purchasing shares at any point between now and then"?
If you don't mind me asking, logically how did you determine that $.002s would be a good entry point?
Very nice to keep a sense of humor while we make our way through this changing world.
Very nice photo.
Reminds us everyday of the values that lead to the founding of the country and the rights and freedoms those founders sought to guarantee, in a document that is often overlooked and ignored.
I personally like the freedom to invest in a company, with the promise of CTIX. I also like that a companies, like CTIX, still feel that this country offers the best place to start and grow a biopharma company. Looking for big things in the coming months.
Crazy day!
NVIV opens at $1.76 and moves up to $2.17 on no news.
Decided to sell most of the rest of my shares at $2.05, but bought a small amount back at $1.81. Will be looking to add more shares on any dips.
Good Luck to all the Longs!
I knew our regulars couldn't stay away for long. Nice to see everybody back.
I don't know about anybody else, but I expect a little volatility moving forward. NAVB price range for yesterday was: $1.70-$2.20.
Today: $1.92-$2.12.
One thing I do know is that we will hear from NAVB posters regarding the price action.
Hope some of our regular posters didn't miss the 12% bump today.
I know we still have a ways to go to get most of us green, but after the last few months, I'll take a green day.
Let's find a support level and wait for more news.
Nice move today-12%.
Sold half of my position when NVIV was near $2, but can't bring myself to sell all.
Could be wishful thinking, but I'm hoping NVIV can make a difference to those that deal with spinal cord injuries.
Depending on the reason for the PPS drop, I would be a buyer on any PPS near the 52 week low.
PPS is near the same as it was 6 months ago, and down 20% from where is was 2 months ago.
Orphan drug designation Nov. 13---nothing
I agree,doesn't look like anything but an outside intervention (partnership or investment) will move this stock.
I don't know where the PPS will head for DVAX, in the short term, but feel that Heplisav has a good chance to be approved in Europe in 2014.
Dynavax will initiate a 8000 patient phase 3 trial in 2014, with data to be release in 2016 and possible approval for Heplisav in the U.S. with in a year of the data release.
I liked the clinical profile of Heplisav when it was reviewed by the FDA earlier this year, and felt is should have been approved.
Dynavax also has two other clinical programs in phase I and in pre-clinical research.
Hopeful for good news from Europe, which will move the stock higher, but for the most part I believe to get maximum value, as long as there are no surprises, we may have to wait a few years for the big payoff.
Does ANYONE on these boards recognize SARCASM when they see it?
Please try to find the context of the comment or check the comments I am responding to, before making your comment, or not.
For the record, why not be happy with 41% ytd, but I guess some people expect a 3 or 4 bagger every year.
YTD return 2013: 41%.
Could be worse, and according to ONCS website, clinical data could be released at anytime.
Good call on the pps.
Any update from the charts?
DVAX moving higher.
Volume is good and institutional ownership at 78%.
PPS: up 50% this month
down over 30% for 6 and 12 month period.
Not to paint a rosy picture of this stock, since I have owned over the last 6 and 12 months, but it is nice to see this price reversal.
I think there is plenty to like about DVAX and Heplisav AND, somebody is buying shares.
I think I'll ride DVAX it little longer and see where we go.
E-Man,
I agree, bad data can surely move INO pps lower.
I also agree that the history of the company has some failed trials and inability, at this point, to move candidates forward from pre-clinical and phase I.
We continue to see good pre-clinical data and we recently we have seen plans for and some progression with clinical trials.
My original statement was addressed to the few outspoken posters that were and are predicting that INO pps will decline. They site failures of past, and some TA that they say point to imminent price declines. I do not find these arguments compelling and feel that INO has much more upside than down at this point.
I remain long INO.
Apology extended.
Not everyone on the ihub boards gets my purpose for my posts as well.
We have all types of investors on the INO board. Most of us have either made or are sitting on a fair sized profit. I believe INO is the real deal and is headed higher, could be much higher. Haven't yet heard a good reason why INO pps will go lower.
So, just waiting for some more good news.
Good Luck to all.
Reindeer,
Why would you ask another poster their thoughts on INO, when they have tried and failed to pump a sub-penny stock on another board, and that stock is currently down 75% in the last 3 months?
You should have seen plenty of recent posts on this board, that should have peaked your interest in INO and it's stock for you to do your own DD.